These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 10362788)

  • 1. Activating c-kit gene mutations in human germ cell tumors.
    Tian Q; Frierson HF; Krystal GW; Moskaluk CA
    Am J Pathol; 1999 Jun; 154(6):1643-7. PubMed ID: 10362788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KIT mutations are common in testicular seminomas.
    Kemmer K; Corless CL; Fletcher JA; McGreevey L; Haley A; Griffith D; Cummings OW; Wait C; Town A; Heinrich MC
    Am J Pathol; 2004 Jan; 164(1):305-13. PubMed ID: 14695343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-KIT is frequently mutated in bilateral germ cell tumours and down-regulated during progression from intratubular germ cell neoplasia to seminoma.
    Biermann K; Göke F; Nettersheim D; Eckert D; Zhou H; Kahl P; Gashaw I; Schorle H; Büttner R
    J Pathol; 2007 Nov; 213(3):311-8. PubMed ID: 17768701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations of the c-kit gene in testicular germ cell tumors.
    Sakuma Y; Sakurai S; Oguni S; Hironaka M; Saito K
    Cancer Sci; 2003 Jun; 94(6):486-91. PubMed ID: 12824871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KIT (c-kit oncogene product) pathway is constitutively activated in human testicular germ cell tumors.
    Nakai Y; Nonomura N; Oka D; Shiba M; Arai Y; Nakayama M; Inoue H; Nishimura K; Aozasa K; Mizutani Y; Miki T; Okuyama A
    Biochem Biophys Res Commun; 2005 Nov; 337(1):289-96. PubMed ID: 16188233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAS/MAPK Pathway Driver Alterations Are Significantly Associated With Oncogenic KIT Mutations in Germ-cell Tumors.
    Mata DA; Yang SR; Ferguson DC; Liu Y; Sharma R; Benhamida JK; Al-Ahmadie HA; Chakravarty D; Solit DB; Tickoo SK; Gupta S; Arcila ME; Ladanyi M; Feldman DR; Reuter VE; Vanderbilt CM
    Urology; 2020 Oct; 144():111-116. PubMed ID: 32721511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A variant c-KIT mutation, D816H, fundamental to the sequential development of an ovarian mixed germ cell tumor and systemic mastocytosis with chronic myelomonocytic leukemia.
    Mitchell SG; Bunting ST; Saxe D; Olson T; Keller FG
    Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27781377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A c-KIT codon 816 mutation, D816H, in the testicular germ cell tumor: case report of a Japanese patient with bilateral testicular seminomas.
    Tate G; Suzuki T; Kishimoto K; Mitsuya T
    Acta Med Okayama; 2005 Feb; 59(1):33-6. PubMed ID: 15902997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-KIT codon 816 mutation in a recurrent and metastatic dysgerminoma of a 14-year-old girl: case study.
    Pauls K; Wardelmann E; Merkelbach-Bruse S; Büttner R; Zhou H
    Virchows Arch; 2004 Dec; 445(6):651-4. PubMed ID: 15455230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.
    Furitsu T; Tsujimura T; Tono T; Ikeda H; Kitayama H; Koshimizu U; Sugahara H; Butterfield JH; Ashman LK; Kanayama Y
    J Clin Invest; 1993 Oct; 92(4):1736-44. PubMed ID: 7691885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of c-KIT mutations in gonadoblastoma and dysgerminomas of patients with disorders of sex development (DSD) and ovarian dysgerminomas.
    Hersmus R; Stoop H; van de Geijn GJ; Eini R; Biermann K; Oosterhuis JW; Dhooge C; Schneider DT; Meijssen IC; Dinjens WN; Dubbink HJ; Drop SL; Looijenga LH
    PLoS One; 2012; 7(8):e43952. PubMed ID: 22937135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The diagnostic and predictive role of kit (CD117)].
    Dirnhofer S; Zimpfer A; Went P
    Ther Umsch; 2006 Apr; 63(4):273-8. PubMed ID: 16689459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of c-kit exons 11- and 17-activating mutations in testicular seminomas by high-resolution melting amplicon analysis.
    Willmore-Payne C; Holden JA; Chadwick BE; Layfield LJ
    Mod Pathol; 2006 Sep; 19(9):1164-9. PubMed ID: 16741525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wilms tumor gene 1 (WT1), TP53, RAS/BRAF and KIT aberrations in testicular germ cell tumors.
    Boublikova L; Bakardjieva-Mihaylova V; Skvarova Kramarzova K; Kuzilkova D; Dobiasova A; Fiser K; Stuchly J; Kotrova M; Buchler T; Dusek P; Grega M; Rosova B; Vernerova Z; Klezl P; Pesl M; Zachoval R; Krolupper M; Kubecova M; Stahalova V; Abrahamova J; Babjuk M; Kodet R; Trka J
    Cancer Lett; 2016 Jul; 376(2):367-76. PubMed ID: 27085458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers.
    Hoei-Hansen CE; Kraggerud SM; Abeler VM; Kaern J; Rajpert-De Meyts E; Lothe RA
    Mol Cancer; 2007 Feb; 6():12. PubMed ID: 17274819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.
    Lux ML; Rubin BP; Biase TL; Chen CJ; Maclure T; Demetri G; Xiao S; Singer S; Fletcher CD; Fletcher JA
    Am J Pathol; 2000 Mar; 156(3):791-5. PubMed ID: 10702394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms.
    Ma Y; Longley BJ; Wang X; Blount JL; Langley K; Caughey GH
    J Invest Dermatol; 1999 Feb; 112(2):165-70. PubMed ID: 9989791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
    Shivakrupa R; Bernstein A; Watring N; Linnekin D
    Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
    Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
    Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of a truncated form of the c-Kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer.
    Paronetto MP; Farini D; Sammarco I; Maturo G; Vespasiani G; Geremia R; Rossi P; Sette C
    Am J Pathol; 2004 Apr; 164(4):1243-51. PubMed ID: 15039213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.